Complement anaphylatoxins as immune regulators in cancer
- PMID: 24711204
- PMCID: PMC4303144
- DOI: 10.1002/cam4.241
Complement anaphylatoxins as immune regulators in cancer
Abstract
The role of the complement system in innate immunity is well characterized. However, a recent body of research implicates the complement anaphylatoxins C3a and C5a as insidious propagators of tumor growth and progression. It is now recognized that certain tumors elaborate C3a and C5a and that complement, as a mediator of chronic inflammation and regulator of immune function, may in fact foster rather than defend against tumor growth. A putative mechanism for this function is complement-mediated suppression of immune effector cells responsible for immunosurveillance within the tumor microenvironment. This paradigm accords with models of immune dysregulation, such as autoimmunity and infectious disease, which have defined a pathophysiological role for abnormal complement signaling. Several types of immune cells express the cognate receptors for the complement anaphylatoxins, C3aR and C5aR, and demonstrate functional modulation in response to complement stimulation. In turn, impairment of antitumor immunity has been intimately tied to tumor progression in animal models of cancer. In this article, the literature was systematically reviewed to identify studies that have characterized the effects of the complement anaphylatoxins on the composition and function of immune cells within the tumor microenvironment. The search identified six studies based upon models of lymphoma and ovarian, cervical, lung, breast, and mammary cancer, which collectively support the paradigm of complement as an immune regulator in the tumor microenvironment.
Keywords: Anaphylatoxins; cancer; complement; immune; microenvironment.
© 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Similar articles
-
Complement anaphylatoxins C3a and C5a: Emerging roles in cancer progression and treatment.Semin Cell Dev Biol. 2019 Jan;85:153-163. doi: 10.1016/j.semcdb.2017.11.023. Epub 2017 Nov 23. Semin Cell Dev Biol. 2019. PMID: 29155219 Review.
-
Structural and functional characterization of human and murine C5a anaphylatoxins.Acta Crystallogr D Biol Crystallogr. 2014 Jun;70(Pt 6):1704-17. doi: 10.1107/S139900471400844X. Epub 2014 May 30. Acta Crystallogr D Biol Crystallogr. 2014. PMID: 24914981 Free PMC article.
-
The Preoperative Serum Levels of the Anaphylatoxins C3a and C5a and Their Association with Clinico-Pathological Factors in Breast Cancer Patients.Arch Razi Inst. 2022 Oct 31;77(5):1873-1879. doi: 10.22092/ARI.2022.358193.2173. eCollection 2022 Oct. Arch Razi Inst. 2022. PMID: 37123148 Free PMC article.
-
Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression.J Neurochem. 1999 Jun;72(6):2426-36. doi: 10.1046/j.1471-4159.1999.0722426.x. J Neurochem. 1999. PMID: 10349852
-
Anaphylatoxins spark the flame in early autoimmunity.Front Immunol. 2022 Jul 25;13:958392. doi: 10.3389/fimmu.2022.958392. eCollection 2022. Front Immunol. 2022. PMID: 35958588 Free PMC article. Review.
Cited by
-
Binding of raloxifene to human complement fragment 5a (hC5a): a perspective on cytokine storm and COVID19.J Biomol Struct Dyn. 2022 Feb;40(3):982-994. doi: 10.1080/07391102.2020.1820381. Epub 2020 Sep 15. J Biomol Struct Dyn. 2022. PMID: 32930050 Free PMC article.
-
The tumour microenvironment links complement system dysregulation and hypoxic signalling.Br J Radiol. 2019 Jan;92(1093):20180069. doi: 10.1259/bjr.20180069. Epub 2018 May 15. Br J Radiol. 2019. PMID: 29544344 Free PMC article. Review.
-
Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations.Front Immunol. 2020 Jan 28;10:3097. doi: 10.3389/fimmu.2019.03097. eCollection 2019. Front Immunol. 2020. PMID: 32047495 Free PMC article.
-
Complement component C3aR constitutes a novel regulator for chick eye morphogenesis.Dev Biol. 2017 Aug 1;428(1):88-100. doi: 10.1016/j.ydbio.2017.05.019. Epub 2017 May 30. Dev Biol. 2017. PMID: 28576690 Free PMC article.
-
Bioinformatics analysis of microenvironment-related genes associated with radioresistance in glioblastoma.Transl Cancer Res. 2020 Dec;9(12):7495-7504. doi: 10.21037/tcr-20-2476. Transl Cancer Res. 2020. PMID: 35117350 Free PMC article.
References
-
- Markiewski MM. Lambris JD. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009;30:286–292. doi: 10.1016/j.it.2009.04.002. - DOI - PMC - PubMed
-
- Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008;9:1225–1235. doi: 10.1038/ni.1655. - DOI - PMC - PubMed
-
- Loveland BE. Cebon J. Cancer exploiting complement: a clue or an exception? Nat. Immunol. 2008;9:1205–1206. doi: 10.1038/ni1108-1205. - DOI - PubMed
-
- Ostrand-Rosenberg S. Cancer and complement. Nat. Biotechnol. 2008;26:1348–1349. doi: 10.1038/nbt1208-1348. - DOI - PMC - PubMed
-
- Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA. Parsa AT. Cancer and the complement cascade. Mol. Cancer Res. 2010;8:1453–1465. doi: 10.1158/1541-7786.MCR-10-0225. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources